Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00100789 · FLOW

Participant flow

S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer · Source last updated 2012-10-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients received Gemcitabine 3,000 mg/m2 (IV on days 1 and 15 over 30 minutes) and Paclitaxel 150 mg/m2 (IV on days 1 and 15 over one hour). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 4 additional courses beyond CR.
    id
    FG000
    title
    Gemcitabine and Paclitaxel
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        10
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        42
      type
      Progression/relapse
    4. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death
    5. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Not protocol specified
    6. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Ineligible
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Never received treatment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        67
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        64
      type
      Eligible
    3. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      Eligible and Began Protocol Therapy
    4. achievements
      1. group Id
        FG000
        num Subjects
        3
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        64
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients received Gemcitabine 3,000 mg/m2 (IV on days 1 and 15 over 30 minutes) and Paclitaxel 150 mg/m2 (IV on days 1 and 15 over one hour). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 4 additional courses beyond CR.
    id
    FG000
    title
    Gemcitabine and Paclitaxel
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        10
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        42
      type
      Progression/relapse
    4. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death
    5. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Not protocol specified
    6. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Ineligible
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Never received treatment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        67
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        64
      type
      Eligible
    3. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      Eligible and Began Protocol Therapy
    4. achievements
      1. group Id
        FG000
        num Subjects
        3
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        64
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice